James A. Datin
Former President and CEO, BioAgilytix
James Datin became a member of the Board in August 2019 and serves on the Audit Committee and the Compensation Committee. Mr. Datin is currently President & Chief Executive Officer of BioAgilytix, a leading global bioanalytical contract research organization (CRO) that supports the development of novel therapeutic biologics. Prior to BioAgilytix, Mr. Datin was EVP and Managing Director at Safeguard Scientifics, Inc. (NYSE: SFE), a company focused on providing capital and advice to technology-driven businesses in healthcare, financial services and digital media. Mr. Datin has also served as CEO of Touchpoint Solutions, a software solutions provider; Group President of Dendrite International; Group Director, Corporate Business Strategy and Planning at GlaxoSmithKline; CEO of publicly traded Isuta Holdings Berhad; and Director, International Business at Baxter/Merck KGaA. Mr. Datin previously served on the Boards of Directors of Clarient (NASDAQ: CLRT), NuPathe Inc. (NASDAQ: PATH), the University City Science Center (Philadelphia) and Laurate Pharma. Mr. Datin earned a B.B.A. at Marshall University, an M.B.A. at the University of New Haven and an Advanced Management Degree at The Wharton School at The University of Pennsylvania.